Adagene Inc.
corporate_fare Company Profile
Adagene Inc. (NASDAQ:ADAG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for ADAG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ADAG spans 6-K, SCHEDULE 13D/A, 424B5, 20-F.
Recent high-impact activity:
- Adagene, City of Hope Launch Phase 1 Muzastotug/Ivonescimab Trial in MSS Colorectal Cancer
- Adagene Completes Phase 2 Enrollment, Triggering $8M Sanofi Second Closing
- Adagene Completes 60-Patient Enrollment in Randomized Phase 2 Muzastotug/KEYTRUDA Colorectal Trial
- Adagene Secures NMPA Clearance to Launch Phase 1 Trial for ADG138, a Double-Masked HER2xCD3 T-Cell Engager
- NMPA Clears Adagene's IND for ADG138, a Double-Masked HER2xCD3 T-Cell Engager
Financial Snapshot
Short Interest & Short Volume
11.83 days to coverFINRA reported short interest of 2,174,270 shares in ADAG as of the October 30, 2026 settlement, a 2.7% increase from the prior period — about 11.8 days to cover at its recent average daily volume. On November 20, 2026, 30.3% of ADAG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
ADAG files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.